Compare Quest Diagnostics Inc (DGX) vs Hewlett Packard Enterprise Co (HPE) Price & Performance

Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.

DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.

Hewlett Packard Enterprise (HPE) trades at $70.99, down 1.56% today but near its 52-week high following strong AI-driven momentum. The stock has gained over 160% year-over-year, supported by recent earnings beats and a $1.2 billion AI infrastructure order from Vultr. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals reveal robust revenue growth projections to $41.9 billion in 2026 despite margin compression in 2025.

HPE presents a compelling growth story fueled by AI infrastructure demand, with analyst consensus leaning bullish (47.5% Buy ratings) and a $70.35 price target. Key risks include elevated valuation multiples (P/E 36.6) and execution challenges in integrating Juniper Networks, but raised guidance and institutional upgrades signal confidence in near-term upside.